HRPC, cytotoxic therapy, docetaxel plus estm, conversion of hormone refractory to hormone hypersensitive disease (CROSBI ID 503649)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Novosel, Sunčica ; Kovačić, Ksenija ; Ahel, Zaky ; Kraljić, Ivo ; Kusuć, Zvonko ; Tarle, Marko
engleski
HRPC, cytotoxic therapy, docetaxel plus estm, conversion of hormone refractory to hormone hypersensitive disease
Viciuos cycle involving osteoblasts, osteoclasts and prosate cancer tumors cells in bone, together with several promotors, has been examined. It apprears the among them the progression to osteolysis is best described by chromogranin A concentration with the lead time od about 6 months. In such HRPC several cytotoxic combinations were examined and phase II docetaxel/estm is the therapy of choice.
13th International Prostate Cancer Update
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
91-91-x.
2003.
objavljeno
Podaci o matičnoj publikaciji
Book of Abstracts, 13th International Prostate Cancer Update
E. David Crawford
Denver (CO): icpme
Podaci o skupu
Nepoznat skup
predavanje
29.02.1904-29.02.2096
